Median Diagnostics Inc.

As of December 31, 2025, Median Diagnostics Inc. carries a market capitalization of 18.91B, placing it among publicly traded companies globally. Its enterprise value stands at 7.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Median Diagnostics Inc. has 1.65M shares outstanding.

As of December 31, 2025, Median Diagnostics Inc. trades at a trailing price-to-earnings ratio of 7.97. The price-to-sales ratio is 1.58, and the price-to-book ratio stands at 0.84.

As of December 31, 2025, Median Diagnostics Inc. trades at an EV/EBITDA multiple of 2.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 3.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Median Diagnostics Inc. trades at an EV/FCF ratio of 2.62, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 7.37B versus a market cap of 18.91B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Median Diagnostics Inc. maintains a current ratio of 15.48, meaning it holds 15.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.27, indicating elevated leverage, while an interest coverage ratio of 163.69 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Median Diagnostics Inc. posted a return on equity (ROE) of 11.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.00 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.67, useful for judging operating efficiency across full business cycles. The company generates approximately 173.47M in revenue per employee across its workforce of 69.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.10 indicates how many times Median Diagnostics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Median Diagnostics Inc. recorded 351.53M in income tax expense. That works out to an effective tax rate of 12.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.72B, leaving 2.37B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 2, 2026, Median Diagnostics Inc.'s stock has declined approximately 64.21% over the past 52 weeks. The 50-day moving average sits at 7,028.60, while the 200-day moving average is 10,222.60.

Over the twelve months ended December 31, 2025, Median Diagnostics Inc. generated 11.97B in revenue and converted that into 2.37B in net income, yielding earnings per share of 1,440.28. EBITDA reached 2.56B, while operating income came in at 2.04B.

As of December 31, 2025, Median Diagnostics Inc. holds 12.05B in cash and equivalents against 512.97M in total debt, resulting in a net debt position of -1.69B. Total book value stands at 22.65B, with working capital of 15.64B providing operational flexibility.

Median Diagnostics Inc. produced 3.00B in operating cash flow over the twelve months ended December 31, 2025. After subtracting -207.67M in capital expenditures, free cash flow totaled 2.79B - equivalent to 1,696.56 per share.

Over the twelve months ended December 31, 2025, Median Diagnostics Inc. posted a gross margin of 60.61, reflecting its pricing power and cost economics. The operating margin of 17.08 and net profit margin of 19.82 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 14.78, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Median Diagnostics Inc. shareholders.

As of December 31, 2025, Median Diagnostics Inc. has an Altman Z-Score of 10.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.